AC
OLMA icon

Aristides Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Aristides Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,500
Closed -$189K – 302
2024
Q4 		$189K Buy
+32,500
New +$325K 0.04% 252

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

Aristides Capital's OLMA Position: Q1 2025 in Review

Aristides Capital sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 32,500 shares — an estimated $189K sold.

Aristides Capital first reported a position in OLMA in Q4 2024 and held it in 1 quarter. The position peaked at $189K in Q4 2024. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

  • Aristides Capital reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Aristides Capital sold 32,500 Olema Pharmaceuticals shares in Q1 2025, an estimated $189K.
  • Aristides Capital first reported a position in Olema Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Aristides Capital's Olema Pharmaceuticals position peaked at $189K in Q4 2024.
  • 133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.